| Not Yet Recruiting | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma NCT07365839 | Virginia Commonwealth University | Phase 1 |
| Recruiting | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant NCT07059494 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Recruiting | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma NCT06902246 | University of Miami | Phase 2 |
| Not Yet Recruiting | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma NCT07110233 | University of California, San Francisco | N/A |
| Not Yet Recruiting | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resecta NCT07522411 | BinYong Liang | Phase 1 / Phase 2 |
| Not Yet Recruiting | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) NCT07479485 | Lepu Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors NCT07224568 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma NCT05842174 | VA Office of Research and Development | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Trial of TB511 in Advanced Solid Tumors NCT06400160 | Twinpig Biolab, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment NCT06217094 | University of Florida | Phase 1 |
| Not Yet Recruiting | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer NCT07226063 | Amit Mahipal | Phase 2 |
| Recruiting | Adjuvant TACE in HCC With High-risk Recurrence Factors NCT07417397 | Guangxi Medical University | Phase 3 |
| Not Yet Recruiting | A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune NCT07368023 | Ningbo Medical Center Lihuili Hospital | — |
| Recruiting | First in Human Study of SIM0610 in Solid Tumors NCT07348211 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma NCT07324824 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma NCT07356037 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | MR 7700 Multinuclear Application Clinical Study NCT07368049 | Philips Clinical & Medical Affairs Global | N/A |
| Not Yet Recruiting | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661 | AccSalus Biosciences, Inc. | Phase 1 |
| Not Yet Recruiting | Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unrese NCT07281664 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Not Yet Recruiting | SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitor NCT07341321 | Medical University of Graz | — |
| Recruiting | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma NCT07317414 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted I NCT07309419 | Shanghai Zhongshan Hospital | Phase 2 / Phase 3 |
| Recruiting | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-speci NCT07148050 | Seattle Children's Hospital | Phase 1 |
| Not Yet Recruiting | A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune NCT07310836 | Ningbo Medical Center Lihuili Hospital | — |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348 | Replimune, Inc. | — |
| Recruiting | Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Ca NCT07485114 | Daniel Keizman | — |
| Recruiting | A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma NCT07116486 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma NCT07179900 | Hebei Medical University Fourth Hospital | Phase 2 |
| Recruiting | Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatoc NCT07243691 | Sir Run Run Shaw Hospital | N/A |
| Recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combinatio NCT07227012 | Pfizer | Phase 1 / Phase 2 |
| Enrolling By Invitation | Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After NCT07290764 | Fujian Provincial Hospital | — |
| Not Yet Recruiting | New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules NCT07272083 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma NCT07274774 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcin NCT06904170 | UNICANCER | Phase 2 / Phase 3 |
| Recruiting | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424 | Diwakar Davar | Phase 2 |
| Recruiting | Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoin NCT07235410 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Recruiting | A Study of ZW251 in Participants With Advanced Solid Tumors NCT07164313 | Zymeworks BC Inc. | Phase 1 |
| Recruiting | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma NCT06880523 | Canadian Cancer Trials Group | Phase 2 |
| Not Yet Recruiting | GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma NCT07209813 | Beijing Gene Key Life Technology Co., Ltd | Phase 2 |
| Not Yet Recruiting | The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Mult NCT07180459 | Xuhua Duan | — |
| Recruiting | Phase II Trial of Immunonutrition in Hepatectomy NCT07395635 | Tata Memorial Centre | N/A |
| Recruiting | JMT106 Injection in the Treatment of Advanced Solid Tumors NCT07275073 | Shanghai JMT-Bio Inc. | Phase 1 |
| Recruiting | Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide NCT07429864 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Not Yet Recruiting | 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) NCT06852820 | Melissa Lumish | Phase 2 |
| Not Yet Recruiting | LTFU for All Cell and Gene Therapy Studies NCT06194461 | AstraZeneca | — |
| Recruiting | Y-90 Treatment Response Using Transarterial Radioembolization NCT07145801 | Thomas Jefferson University | Phase 2 |
| Not Yet Recruiting | Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatoce NCT07157306 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tu NCT07159048 | Fudan University | N/A |
| Recruiting | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | IDOV-Immune for Advanced Solid Tumors NCT06910657 | ViroMissile, Inc. | Phase 1 |
| Not Yet Recruiting | AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy NCT07118735 | National Cheng-Kung University Hospital | N/A |
| Completed | Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients NCT07404566 | Benha University | — |
| Recruiting | TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy an NCT07100405 | Fudan University | — |
| Active Not Recruiting | Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologi NCT05613621 | National Health Research Institutes, Taiwan | — |
| Not Yet Recruiting | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injec NCT07131501 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellul NCT07081633 | AstraZeneca | Phase 2 |
| Not Yet Recruiting | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellu NCT07078305 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prosp NCT07064668 | Tongji Hospital | Phase 2 |
| Recruiting | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC NCT06294548 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Recruiting | BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligomet NCT07062055 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma NCT07091942 | National Taiwan University Hospital | — |
| Recruiting | HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receivin NCT06899152 | Montefiore Medical Center | N/A |
| Active Not Recruiting | LEAF(Liver Tumor dEtection And classiFication AI) NCT06859840 | Zhejiang University | N/A |
| Not Yet Recruiting | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC NCT06984718 | Akeso | Phase 2 |
| Recruiting | Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimu NCT06796114 | Centre Hospitalier Universitaire de Besancon | N/A |
| Recruiting | PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma NCT07018518 | Chinese PLA General Hospital | Phase 1 |
| Recruiting | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells NCT06198296 | Baylor College of Medicine | Phase 1 |
| Recruiting | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma NCT06954467 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Recruiting | Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev fo NCT06819566 | Asan Medical Center | Phase 2 |
| Recruiting | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Tr NCT06921785 | AstraZeneca | Phase 3 |
| Recruiting | Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High NCT06658782 | University of Oxford | — |
| Recruiting | Imjudo & Imfinzi PMS NCT06544629 | AstraZeneca | — |
| Not Yet Recruiting | Efficacy and Safety of Liver Transplantation for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: a Sin NCT06928415 | Zhejiang University | — |
| Recruiting | Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma NCT06950827 | West China Hospital | — |
| Recruiting | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC NCT06553885 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours NCT06795022 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Live NCT07048665 | Superior University | — |
| Recruiting | Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors NCT06940102 | Changchun GeneScience Pharmaceutical Co., Ltd. | — |
| Recruiting | Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma NCT06551272 | Center Eugene Marquis | Phase 2 |
| Recruiting | A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezo NCT07246668 | Yonsei University | Phase 2 |
| Not Yet Recruiting | Sialic Acid in Hepatocellular Carcinoma NCT06836518 | Sohag University | — |
| Not Yet Recruiting | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint NCT06867432 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TAC NCT06823050 | Xuhua Duan | — |
| Not Yet Recruiting | Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC NCT05195294 | Lion TCR Pte. Ltd. | Phase 2 |
| Recruiting | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Adv NCT06764316 | Bayer | Phase 1 |
| Active Not Recruiting | naVIGation Invitations Liver surveillANce upTake NCT06635694 | Imperial College London | — |
| Recruiting | The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) NCT06789757 | Inova Health Care Services | Phase 2 |
| Not Yet Recruiting | Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) NCT06836778 | Institute of Liver and Biliary Sciences, India | N/A |
| Not Yet Recruiting | Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field NCT06798194 | Chinese PLA General Hospital | — |
| Recruiting | Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab NCT06710223 | University of California, San Diego | Phase 1 |
| Not Yet Recruiting | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcino NCT06538935 | Fujian Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma NCT06708650 | Guiping People's Hospital | N/A |
| Recruiting | TACE Combined Surgery for the Resectable Huge HCC NCT06898398 | Sun Yat-sen University | — |
| Recruiting | Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma NCT06446154 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and NCT06679985 | Coherus Oncology, Inc. | Phase 2 |
| Recruiting | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) NCT06698250 | Anwaar Saeed | Phase 2 |
| Recruiting | TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma NCT06740370 | Sun Yat-sen University | N/A |
| Recruiting | Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment NCT06537193 | Asan Medical Center | N/A |
| Recruiting | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh NCT06526104 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Recruiting | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma NCT05669339 | University of Florida | Phase 2 |
| Not Yet Recruiting | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma NCT06645314 | BioSyngen Pte Ltd | EARLY_Phase 1 |
| Recruiting | Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepat NCT06475118 | CHU de Reims | N/A |
| Enrolling By Invitation | Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrh NCT06624189 | NYU Langone Health | — |
| Recruiting | Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH NCT06813508 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patie NCT07252323 | Yonsei University | N/A |
| Not Yet Recruiting | Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Pro NCT05293158 | Medical University of Graz | N/A |
| Not Yet Recruiting | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma NCT06464380 | Ain Shams University | Phase 4 |
| Recruiting | Psychoeducational Intervention for Patients With Hepatocellular Carcinoma NCT06541990 | Massachusetts General Hospital | N/A |
| Recruiting | Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Tra NCT06767579 | Yonsei University | — |
| Recruiting | Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellula NCT06558227 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Recruiting | Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) NCT06077591 | Chinese University of Hong Kong | N/A |
| Recruiting | HAIC Compared With TACE in Huge Hepatocellular Carcinoma NCT06641713 | Sun Yat-sen University | — |
| Not Yet Recruiting | Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line System NCT06592612 | Sun Yat-sen University | Phase 2 |
| Recruiting | Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC NCT06609876 | Sun Yat-sen University | N/A |
| Recruiting | Organoid Models of Hepatocellular Carcinoma NCT06929845 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT NCT06622031 | Sun Yat-sen University | N/A |
| Recruiting | Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) NCT06602011 | Fujian Provincial Hospital | — |
| Recruiting | A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) NCT06590246 | Shanghai AbelZeta Ltd. | Phase 1 / Phase 2 |
| Completed | Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC NCT06620510 | GC Cell Corporation | — |
| Recruiting | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) NCT06530251 | Akeso | Phase 1 / Phase 2 |
| Recruiting | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC NCT06467799 | Sun Yat-sen University | Phase 2 |
| Recruiting | The Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Hepatocellular Carc NCT06549829 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma NCT06864221 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease NCT06523608 | University Hospital Muenster | — |
| Recruiting | Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma NCT06632717 | National Taiwan University Hospital | Phase 2 |
| Recruiting | Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk NCT06577272 | Tian'an Jiang | — |
| Recruiting | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma NCT06542796 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017 | Nammi Therapeutics Inc | Phase 1 |
| Recruiting | Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma NCT06581315 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Not Yet Recruiting | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Ri NCT06546280 | Zhujiang Hospital | Phase 2 |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Recruiting | Early Detection of Liver Cancer by QUS NCT06345508 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Completed | EchoTip AcuCore Post-Market Clinical Study NCT06358001 | Cook Research Incorporated | — |
| Recruiting | A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Particip NCT06371157 | Akeso | Phase 3 |
| Recruiting | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598 | Replimune, Inc. | Phase 2 |
| Recruiting | Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC NCT06519721 | RenJi Hospital | N/A |
| Recruiting | Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC NCT06537908 | Shanghai Zhongshan Hospital | — |
| Not Yet Recruiting | Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma NCT06543030 | Assiut University | — |
| Recruiting | Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Ca NCT06519578 | RenJi Hospital | N/A |
| Not Yet Recruiting | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma NCT06512467 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone NCT06526338 | Robert C. Martin | Phase 2 |
| Recruiting | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combinat NCT06498622 | Anhui Provincial Hospital | Phase 2 |
| Not Yet Recruiting | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma NCT06475287 | Fudan University | Phase 2 |
| Recruiting | Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT NCT06334965 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular NCT06096779 | Genentech, Inc. | Phase 2 |
| Recruiting | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC NCT06478693 | Myeloid Therapeutics | Phase 1 |
| Recruiting | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carci NCT06463522 | Beijing 302 Hospital | Phase 1 / Phase 2 |
| Recruiting | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma NCT06623474 | Nanfang Hospital, Southern Medical University | — |
| Unknown | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for NCT05711823 | Guangxi Medical University | Phase 3 |
| Recruiting | To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoem NCT06478719 | Febico Biomedical Corp. | Phase 1 / Phase 2 |
| Not Yet Recruiting | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-labe NCT06482008 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion NCT06089369 | Tongji Hospital | Phase 3 |
| Not Yet Recruiting | Navigating the Clinical Trial Process for Hepatocellular Carcinoma NCT05859945 | Power Life Sciences Inc. | — |
| Recruiting | Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma NCT06961617 | Lion TCR Pte. Ltd. | Phase 1 |
| Recruiting | Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Thera NCT06607120 | Zhongda Hospital | — |
| Withdrawn | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC NCT06361758 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enliste NCT06218420 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Recruiting | Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy NCT06379256 | Chang Gung Memorial Hospital | — |
| Recruiting | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC NCT06061276 | Sun Yat-sen University | N/A |
| Recruiting | bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma NCT06070636 | Sun Yat-sen University | N/A |
| Recruiting | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment NCT06406634 | Hunan Cancer Hospital | Phase 2 |
| Recruiting | Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Th NCT06382103 | Shanghai Zhongshan Hospital | — |
| Not Yet Recruiting | PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C He NCT06423144 | Shanghai Zhongshan Hospital | — |
| Withdrawn | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) NCT06337162 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Recruiting | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially NCT06405061 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thr NCT06389422 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial fo NCT06364787 | Beijing 302 Hospital | Phase 1 |
| Not Yet Recruiting | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of NCT06364800 | Beijing 302 Hospital | EARLY_Phase 1 |
| Recruiting | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT NCT06349317 | Yongyi Zeng | Phase 2 |
| Completed | Brazilian Reality of Hepatocellular Carcinoma NCT06230328 | AstraZeneca | — |
| Recruiting | Targeted Navigation in Hepatocellular Carcinoma (HCC) NCT06260943 | University of Miami | N/A |
| Recruiting | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) NCT06313190 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma NCT06331260 | Zhejiang University | — |
| Recruiting | Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma NCT06272656 | Hebei Medical University Third Hospital | — |
| Not Yet Recruiting | Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma NCT06331273 | Zhejiang University | — |
| Unknown | The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirr NCT06328283 | Sohag University | — |
| Not Yet Recruiting | Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on C NCT06317896 | Zhujiang Hospital | — |
| Recruiting | A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Comb NCT06280105 | Meng Chao Hepatobiliary Hospital of Fujian Medical University | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizuma NCT06253598 | The First Affiliated Hospital of Bengbu Medical University | Phase 2 |
| Recruiting | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma NCT06339424 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherap NCT06349044 | Zhejiang Cancer Hospital | N/A |
| Recruiting | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer NCT06342414 | City of Hope Medical Center | — |
| Recruiting | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. NCT06375486 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer NCT06363006 | Peking Union Medical College Hospital | Phase 1 |
| Recruiting | Find HDV and Determine Its Status in Turkey NCT06248580 | Yaşar Bayındır, MD | — |
| Recruiting | Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) NCT06261125 | Mian XI | Phase 2 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Recruiting | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC NCT06364007 | Sulai Liu | Phase 2 |
| Recruiting | Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer NCT06261047 | Shandong Cancer Hospital and Institute | — |
| Active Not Recruiting | A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard NCT06748755 | Superior University | — |
| Recruiting | Immunotherapy for Hepatocellular Carcinoma NCT06241326 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | The Dual Impact of Cirrhosis on Transplantation for Hepatocellular Carcinoma：a Two-center Retrospective Cohort NCT06420791 | Xiao Xu | — |
| Not Yet Recruiting | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection-phase II Clini NCT06193733 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy NCT05901519 | University of Michigan Rogel Cancer Center | Phase 2 |
| Unknown | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or NCT05910970 | Guangxi Medical University | Phase 3 |
| Recruiting | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Car NCT06326502 | Etnova Therapeutics Corp. | Phase 1 |
| Recruiting | Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantatio NCT06236568 | Azienda Ospedaliero-Universitaria di Modena | N/A |
| Unknown | Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood NCT06544083 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastase NCT06265350 | Sun Yat-sen University | N/A |
| Active Not Recruiting | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery NCT06204159 | Abramson Cancer Center at Penn Medicine | N/A |
| Unknown | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy NCT06247293 | Zhujiang Hospital | — |
| Enrolling By Invitation | Project OASIS: Optimizing Approaches to Select Implementation Strategies NCT06061328 | VA Office of Research and Development | N/A |
| Recruiting | Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma NCT06694636 | Zhongda Hospital | N/A |
| Not Yet Recruiting | A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Car NCT06196775 | Harbin Medical University | Phase 2 |
| Recruiting | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. NCT06205472 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thro NCT06233981 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability NCT05223816 | Virogin Biotech Canada Ltd | Phase 2 |
| Recruiting | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib NCT06478927 | Henan Cancer Hospital | N/A |
| Recruiting | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous NCT06109272 | AbbVie | Phase 2 / Phase 3 |
| Unknown | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant T NCT06182644 | Guangdong Provincial People's Hospital | N/A |
| Recruiting | Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC NCT05971108 | Manchester University NHS Foundation Trust | N/A |
| Recruiting | ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery NCT06204835 | Institute of Automation, Chinese Academy of Sciences | Phase 1 |
| Recruiting | Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies NCT05803928 | Hua Li | Phase 1 |
| Not Yet Recruiting | Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma . NCT06168357 | Assiut University | — |
| Recruiting | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of U NCT06244225 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. NCT06669377 | Zhongda Hospital | — |
| Recruiting | Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors NCT06179602 | Leiden University Medical Center | — |
| Recruiting | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcin NCT06201065 | Sun Yat-sen University | Phase 3 |
| Unknown | Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinom NCT06178809 | Singlera Genomics Inc. | — |
| Recruiting | DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC NCT06190665 | Zhongda Hospital | N/A |
| Unknown | Open Versus Laparoscopic Ablation of Liver Malignancies NCT06304766 | Rigshospitalet, Denmark | N/A |
| Active Not Recruiting | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma NCT06084884 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Fa NCT06031818 | Maastricht University | — |
| Active Not Recruiting | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors NCT06205706 | BioInvent International AB | Phase 1 / Phase 2 |
| Recruiting | A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer NCT06005740 | TORL Biotherapeutics, LLC | Phase 1 |
| Unknown | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Adva NCT06285019 | Fudan University | Phase 2 |
| Recruiting | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma NCT06034977 | Chang Gung Memorial Hospital | Phase 2 |
| Completed | Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC NCT06435013 | Sun Yat-sen University | — |
| Withdrawn | Y-90 Versus SBRT for Inoperable HCC NCT05157451 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules NCT06184152 | University of Texas Southwestern Medical Center | N/A |
| Recruiting | Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thromb NCT06166576 | Seoul National University Hospital | Phase 2 |
| Recruiting | Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable NCT05970666 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid NCT06084481 | AbbVie | Phase 1 |
| Recruiting | Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma NCT06178198 | Seoul National University Hospital | Phase 2 |
| Enrolling By Invitation | Validation of SMS Protocol for HCC Screening in High-risk Patients NCT05429190 | Erasmus Medical Center | — |
| Active Not Recruiting | TheraSphere With Durvalumab and Tremelimumab for HCC NCT05063565 | Boston Scientific Corporation | Phase 2 |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Unknown | NWRD06 DNA Plasmid for HCC After Radical Resection NCT06088459 | Newish Technology (Beijing) Co., Ltd. | Phase 1 |
| Recruiting | A Prototype AI Algorithm Versus Liver Imaging Reporting and Data System (LI-RADS) Criteria in Diagnosing HCC o NCT06626087 | The University of Hong Kong | N/A |
| Unknown | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards NCT05681949 | Charite University, Berlin, Germany | N/A |
| Unknown | Follow up After TACE by Elastography and Color Doppler. NCT06070623 | Assiut University | — |
| Not Yet Recruiting | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vei NCT06089382 | Tongji Hospital | Phase 3 |
| Unknown | Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors NCT06031480 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC NCT06041477 | Sun Yat-sen University | Phase 3 |
| Recruiting | Durvalumab and Tremelimumab in Resectable HCC NCT05440864 | University Health Network, Toronto | Phase 2 |
| Unknown | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inh NCT05962450 | Beijing YouAn Hospital | Phase 2 |
| Unknown | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent NCT06075849 | Panolos Bioscience | Phase 1 |
| Unknown | Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study NCT06101758 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Not Yet Recruiting | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma NCT06111326 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC NCT05537402 | University of Texas Southwestern Medical Center | Phase 2 |
| Active Not Recruiting | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoni NCT05822752 | AbbVie | Phase 2 |
| Active Not Recruiting | Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) NCT05953337 | ABK Biomedical | N/A |
| Completed | Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small He NCT06086002 | Seoul National University Hospital | N/A |
| Unknown | Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention o NCT06039280 | Institute of Liver and Biliary Sciences, India | N/A |
| Not Yet Recruiting | Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular C NCT05975463 | HuiKai Li | Phase 2 |
| Active Not Recruiting | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated L NCT05904886 | Hoffmann-La Roche | Phase 3 |
| Recruiting | 18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma NCT05871892 | University of Aarhus | N/A |
| Unknown | A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma ( NCT06023147 | Xuhua Duan | N/A |
| Active Not Recruiting | Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma NCT05622136 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy NCT05263830 | Assistance Publique - Hôpitaux de Paris | — |
| Terminated | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular C NCT05044676 | Assistance Publique - Hôpitaux de Paris | — |
| Terminated | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Pr NCT05582018 | Techsomed Medical Technologies LTD | N/A |
| Recruiting | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma NCT05954897 | Guangdong Provincial People's Hospital | Phase 2 |
| Not Yet Recruiting | Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma NCT05971628 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clini NCT06031285 | Sun Yat-sen University | Phase 2 |
| Unknown | A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. NCT06134973 | Tianjin Third Central Hospital | — |
| Not Yet Recruiting | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With NCT05976568 | Qilu Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT NCT05984511 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Terminated | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. NCT05451862 | Terumo Europe N.V. | N/A |
| Recruiting | Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma NCT05687747 | National University Hospital, Singapore | Phase 1 |
| Unknown | Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC NCT06001567 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | SIRT for Potentially Resectable HCC NCT05994859 | Second Affiliated Hospital of Guangzhou Medical University | N/A |
| Recruiting | Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC NCT05992584 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Completed | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE NCT06041425 | The First Affiliated Hospital with Nanjing Medical University | Phase 4 |
| Unknown | Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy NCT06062706 | King Faisal Specialist Hospital & Research Center | — |
| Unknown | Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surg NCT05970159 | Shanghai Zhongshan Hospital | — |
| Suspended | Immunotherapy for Advanced Liver Cancer NCT05033522 | Mirror Biologics, Inc. | Phase 2 / Phase 3 |
| Unknown | Predictors of Sorafenib Response in HCC NCT05967429 | Sohag University | — |
| Not Yet Recruiting | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellula NCT05897138 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer NCT06007846 | Inova Health Care Services | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrho NCT07193316 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma NCT06138769 | Asan Medical Center | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Recruiting | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens NCT05935189 | Nikomed Medical Center | — |
| Unknown | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma NCT05903456 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC NCT05718882 | RenJi Hospital | N/A |
| Unknown | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma NCT04797884 | THERABIONIC INC. | Phase 2 / Phase 3 |
| Not Yet Recruiting | Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma NCT05908916 | Yonsei University | Phase 2 |
| Withdrawn | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Pr NCT05641922 | Techsomed Medical Technologies LTD | N/A |
| Recruiting | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage I NCT05920863 | Zhejiang Cancer Hospital | Phase 2 |
| Withdrawn | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant NCT05564338 | BeiGene | Phase 3 |
| Recruiting | Liver Cancer and Immunotherapy in the Liquid Biopsy Era NCT05810402 | University Hospital, Montpellier | N/A |
| Recruiting | Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation NCT05475613 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Unknown | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) NCT05897268 | Fudan University | Phase 2 |
| Enrolling By Invitation | Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC NCT06773260 | Azienda Ospedaliero Universitaria Policlinico Modena | — |
| Unknown | Hepatocellular Carcinoma Liver Organoids NCT06355700 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Not Yet Recruiting | Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative NCT05887505 | Taoyuan General Hospital | N/A |